Drug Trial Radar · NCT03029208
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
Last checked: Nov 19, 2026Latest source record: Oct 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
312
Actual
Start
May 11, 2017
Primary completion
Sep 24, 2020
Study completion Sep 24, 2020
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this multi-center study is to evaluate the efficacy and safety of daprodustat in subjects with anemia associated with CKD.
Conditions
- Anaemia
Interventions
DaprodustatDrug
Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
Darbepoetin alfaDrug
Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
Iron therapyDrug
Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52)Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)
Locations
111 sites in 15 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Cerritos, California
GSK Investigational Site
Escondido, California
GSK Investigational Site
Glendale, California
GSK Investigational Site
La Palma, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Lynwood, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Whittier, California
GSK Investigational Site
Middlebury, Connecticut
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Augusta, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Crystal Lake, Illinois
GSK Investigational Site
Fort Wayne, Indiana
GSK Investigational Site
Merrillville, Indiana
GSK Investigational Site
Michigan City, Indiana
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
Baton Rouge, Louisiana
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Jackson, Mississippi
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
Buffalo, New York
GSK Investigational Site
Mineola, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Lufkin, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Hampton, Virginia
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Formosa, Argentina
GSK Investigational Site
Mendoza, Argentina
GSK Investigational Site
San Miguel de Tucumán, Argentina
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.